<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort</title>
				<funder>
					<orgName type="full">Takeda</orgName>
				</funder>
				<funder>
					<orgName type="full">Chiesi</orgName>
				</funder>
				<funder>
					<orgName type="full">Grifols</orgName>
				</funder>
				<funder>
					<orgName type="full">Novartis</orgName>
				</funder>
				<funder>
					<orgName type="full">MundiPharma</orgName>
				</funder>
				<funder>
					<orgName type="full">Boehringer Ingelheim</orgName>
				</funder>
				<funder>
					<orgName type="full">GSK</orgName>
				</funder>
				<funder>
					<orgName type="full">Cipla</orgName>
				</funder>
				<funder>
					<orgName type="full">CSL Behring</orgName>
				</funder>
				<funder>
					<orgName type="full">Roche</orgName>
				</funder>
				<funder>
					<orgName type="full">AstraZeneca</orgName>
				</funder>
				<funder>
					<orgName type="full">Bundesministerium fuer Bildung und Forschung BMBF</orgName>
				</funder>
				<funder>
					<orgName type="full">GlaxoSmithKline</orgName>
				</funder>
				<funder>
					<orgName type="full">CSL-Behring</orgName>
				</funder>
				<funder>
					<orgName type="full">Berlin Chemie/Menarini</orgName>
				</funder>
				<funder>
					<orgName type="full">BMBF Competence Network Asthma and COPD (ASCONET)</orgName>
				</funder>
				<funder ref="#_xvzkKHV #_Jca7jD4 #_etF6HK8">
					<orgName type="full">German Federal Ministry of Education and Research</orgName>
				</funder>
				<funder ref="#_ZWDZRTM #_FzSwT6u">
					<orgName type="full">German Federal Ministry of Education and Research (BMBF)</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
				</availability>
				<date type="published" when="2017-05-15">May 15, 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Kathrin</forename><surname>Kahnert</surname></persName>
							<email>kathrin.kahnert@med.uni-muenchen.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Internal Medicine V</orgName>
								<orgName type="department" key="dep2">Comprehensive Pneumology Center</orgName>
								<orgName type="department" key="dep3">German Center for Lung Research</orgName>
								<orgName type="institution">University of Munich</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tanja</forename><surname>Lucke</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine</orgName>
								<address>
									<addrLine>Ludwig-Maximilians-Universita ¨t Mu ¨nchen</addrLine>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rudolf</forename><forename type="middle">M</forename><surname>Huber</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Internal Medicine V</orgName>
								<orgName type="department" key="dep2">Comprehensive Pneumology Center</orgName>
								<orgName type="department" key="dep3">German Center for Lung Research</orgName>
								<orgName type="institution">University of Munich</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ju</forename><surname>¨rgen Behr</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Internal Medicine V</orgName>
								<orgName type="department" key="dep2">Comprehensive Pneumology Center</orgName>
								<orgName type="department" key="dep3">German Center for Lung Research</orgName>
								<orgName type="institution">University of Munich</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Biertz</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Institute for Biostatistics</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anja</forename><surname>Vogt</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Klinik und Poliklinik</orgName>
								<orgName type="institution">Universita ¨t Mu ¨nchen</orgName>
								<address>
									<settlement>Stoffwechselambulanz Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Henrik</forename><surname>Watz</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Airway Research Center North</orgName>
								<orgName type="department" key="dep2">German Center for Lung Research, Grosshansdorf</orgName>
								<orgName type="institution">Pulmonary Research Institute at LungenClinic Grosshansdorf</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Alter</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Medicine, Pulmonary and Critical Care Medicine</orgName>
								<orgName type="institution" key="instit1">University Medical Center Giessen and Marburg</orgName>
								<orgName type="institution" key="instit2">Philipps-University Marburg</orgName>
								<address>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="institution">Klinik fu ¨r Innere</orgName>
								<address>
									<addrLine>Medizin I Arnold-Heller-Str. 3</addrLine>
									<postCode>24105</postCode>
									<settlement>Kiel</settlement>
									<country>Haus</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sebastian</forename><surname>Fa ¨hndrich</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">German Center for Lung Research (DZL)</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Robert</forename><surname>Bals</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">German Center for Lung Research (DZL)</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine</orgName>
								<address>
									<addrLine>Ludwig-Maximilians-Universita ¨t Mu ¨nchen</addrLine>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">German Center for Lung Research (DZL)</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rolf</forename><surname>Holle</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Institute of Health Economics and Health Care Management</orgName>
								<orgName type="department" key="dep2">German Center for Lung Research</orgName>
								<orgName type="department" key="dep3">Comprehensive Pneumology Center</orgName>
								<orgName type="institution" key="instit1">Helmholtz Zentrum Mu ¨nchen (GmbH) - German Research Center for Environmental Health</orgName>
								<orgName type="institution" key="instit2">Munich (CPC-M)</orgName>
								<address>
									<settlement>Neuherberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Karrasch</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine</orgName>
								<address>
									<addrLine>Ludwig-Maximilians-Universita ¨t Mu ¨nchen</addrLine>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Institute of Epidemiology I</orgName>
								<orgName type="institution">Helmholtz Zentrum Mu ¨nchen -German Research Center for Environmental Health</orgName>
								<address>
									<settlement>Neuherberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sandra</forename><surname>So ¨hler 10</surname></persName>
							<affiliation key="aff10">
								<orgName type="laboratory">ASCONET Study Coordination Office</orgName>
								<orgName type="institution">University of Marburg</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Margarethe</forename><surname>Wacker</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Institute of Health Economics and Health Care Management</orgName>
								<orgName type="department" key="dep2">German Center for Lung Research</orgName>
								<orgName type="department" key="dep3">Comprehensive Pneumology Center</orgName>
								<orgName type="institution" key="instit1">Helmholtz Zentrum Mu ¨nchen (GmbH) - German Research Center for Environmental Health</orgName>
								<orgName type="institution" key="instit2">Munich (CPC-M)</orgName>
								<address>
									<settlement>Neuherberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joachim</forename><forename type="middle">H</forename><surname>Ficker</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Respiratory Medicine, Allergology and Sleep Medicine</orgName>
								<orgName type="institution" key="instit1">General Hospital Nuernberg</orgName>
								<orgName type="institution" key="instit2">Paracelsus Medical University</orgName>
								<address>
									<settlement>Nuernberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Klaus</forename><forename type="middle">G</forename><surname>Parhofer</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Internal Medicine IV</orgName>
								<orgName type="institution">University of Munich</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claus</forename><surname>Vogelmeier</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Medicine, Pulmonary and Critical Care Medicine</orgName>
								<orgName type="institution" key="instit1">University Medical Center Giessen and Marburg</orgName>
								<orgName type="institution" key="instit2">Philipps-University Marburg</orgName>
								<address>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="institution">Klinik fu ¨r Innere</orgName>
								<address>
									<addrLine>Medizin I Arnold-Heller-Str. 3</addrLine>
									<postCode>24105</postCode>
									<settlement>Kiel</settlement>
									<country>Haus</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rudolf</forename><forename type="middle">A Jo</forename><surname>¨rres</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine</orgName>
								<address>
									<addrLine>Ludwig-Maximilians-Universita ¨t Mu ¨nchen</addrLine>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Boehringer</forename><surname>Ingelheim</surname></persName>
						</author>
						<author>
							<persName><roleName>Pfizer</roleName><forename type="first">Pharma</forename><surname>Gmbh</surname></persName>
						</author>
						<author>
							<persName><surname>Co</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chiesi</forename><surname>Kg</surname></persName>
						</author>
						<author>
							<persName><roleName>GlaxoSmithKline, Grifols</roleName><forename type="first">Deutschland</forename><surname>Gmbh</surname></persName>
						</author>
						<author>
							<persName><roleName>MSD</roleName><forename type="first">Sharp</forename><surname>Gmbh</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dohme</forename><surname>Gmbh</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mundipharma</forename><surname>Gmbh</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Deutschland</forename><surname>Novartis</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Takeda</forename><surname>Gmbh</surname></persName>
						</author>
						<author>
							<persName><surname>Pharma</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Herth</forename><surname>Felix</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Beatmungsmedizin</forename><forename type="middle">Amalienstr</forename><surname>Pneumologie</surname></persName>
						</author>
						<author>
							<persName><surname>Heidelberg</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Airway Research Center North</orgName>
								<orgName type="department" key="dep2">German Center for Lung Research, Grosshansdorf</orgName>
								<orgName type="institution">Pulmonary Research Institute at LungenClinic Grosshansdorf</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">Department of Internal Medicine IV</orgName>
								<orgName type="institution">University of Munich</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Innere</forename><surname>Medizin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">V</forename><surname>Abt</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Geb</forename><surname>Pneumologie</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kirrberger</forename><surname>Str</surname></persName>
							<affiliation key="aff10">
								<orgName type="laboratory">ASCONET Study Coordination Office</orgName>
								<orgName type="institution">University of Marburg</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Ralf</forename><forename type="middle">Ewert</forename><surname>Klinik</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Infektiologie</forename><surname>Kliniken</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Su</forename><surname>¨dostbayern</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Geltner</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Margret</forename><surname>Jandl</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hamburg</forename><surname>Berufsgenossenschaftliches</surname></persName>
						</author>
						<author>
							<persName><roleName>Prof</roleName><forename type="first">Universita</forename><surname>¨tsklinikum/</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Andrea</forename><surname>Koch</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Juliane</forename><forename type="middle">Kronsbein</forename><surname>Bergmannsheil</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Klinik</forename><surname>Donaustauf</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Michael</forename><surname>Pfeifer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Zentrum</forename><surname>Fu ¨r</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pneumologie</forename><surname>Ludwigstr</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Donaustauf</forename><surname>Fachkrankenhaus</surname></persName>
						</author>
						<author>
							<persName><roleName>Prof</roleName><forename type="first">Coswig</forename><surname>Gmbh</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Gerd</forename><surname>Ho</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Hugo</forename><forename type="middle">A</forename><surname>Katus</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Medizinische</forename><surname>Fakulta</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Fachklinik</forename><surname>Fu ¨r Lungenerkrankungen</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Stefan</forename><surname>Andreas</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Burkhardt</forename><surname>Bewig</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Campus</forename><surname>Kiel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Forschungszentrum</forename><surname>Borstel</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Peter</forename><surname>Zabel Leibnitz-Zentrum Fu ¨r Medizin</surname></persName>
						</author>
						<author>
							<persName><surname>Biowissenschaften</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Iii</forename><surname>Medizinische</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Klinik</forename><surname>Langenbeckstr</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Internal Medicine V</orgName>
								<orgName type="department" key="dep2">Comprehensive Pneumology Center</orgName>
								<orgName type="department" key="dep3">German Center for Lung Research</orgName>
								<orgName type="institution">University of Munich</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mainz</forename><surname>Universita</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">J</forename><surname>Christian</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Virchow</forename><surname>Zentrum Fu ¨r</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Abt</forename><surname>Fu ¨r Pneumologie</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Rostock</forename><surname>Ruhrlandklinik Ggmbh Essen</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">H</forename><surname>Teschler</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Westdeutsches</forename><surname>Lungenzentrum</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tu</forename><surname>¨schener Weg</surname></persName>
						</author>
						<author>
							<persName><surname>45239 Essen</surname></persName>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">Department of Internal Medicine V -Pulmonology, Allergology, Respiratory Intensive Care Medicine</orgName>
								<orgName type="institution">Saarland University Hospital</orgName>
								<address>
									<settlement>Homburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="institution">National and Kapodistrian University of Athens</orgName>
								<address>
									<country key="GR">GREECE</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="institution">Universita ¨t des Saarlandes</orgName>
								<address>
									<postCode>66424</postCode>
									<settlement>Homburg</settlement>
									<country>Saar</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="department">Kreisklinik Bad Reichenhall Pneumologie</orgName>
								<orgName type="institution">Universita ¨tsmedizin Greifswald</orgName>
								<address>
									<addrLine>Lungenzentrum Su ¨dOst Riedelstraße 5 Bochum Bu ¨rkle-de-la-Camp-Platz 1 44789 Bochum</addrLine>
									<postCode>83435</postCode>
									<settlement>Bad Reichenhall</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="institution">Zentrum fu ¨r Pneumologie</orgName>
								<address>
									<addrLine>Thorax-und Gefa ¨ßchirurgie Neucoswiger Str. 21</addrLine>
									<postCode>01640</postCode>
									<settlement>Coswig</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="department">Pneumologische Lehrklinik der Universita ¨t Go ¨ttingen Philippstiftung e. V</orgName>
								<orgName type="institution">Universita ¨tsklinikum Heidelberg</orgName>
								<address>
									<addrLine>¨t Innere Medizin III Im Nauenheimer Feld Robert-Koch-Str. 3 34376 Immenhausen Universita ¨tsklinikum</addrLine>
									<postCode>672 69120</postCode>
									<settlement>Heidelberg Schleswig-Holstein</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="institution">Universita ¨tsmedizin der Johannes-Gutenberg-Universita ¨t Mainz</orgName>
								<address>
									<addrLine>Prof. Dr. Roland Buhl Schwerpunkt Pneumologie Geba ¨ude 406</addrLine>
									<region>II OG</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-05-15">May 15, 2017</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1371/journal.pone.0177501</idno>
					<note type="submission">Received: March 30, 2017 Accepted: April 30, 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.1" ident="GROBID" when="2025-10-29T00:34+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>¶ Membership of the COSYCONET consortium is provided in the Acknowledgments.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Hyperlipidemia is a major risk factor for cardiovascular diseases which are common comorbidities in patients with chronic obstructive pulmonary disease (COPD) <ref type="bibr" target="#b1">[1]</ref>, but there are only limited studies on its role in COPD itself <ref type="bibr" target="#b2">[2,</ref><ref type="bibr" target="#b3">3]</ref>. Although most comorbidities are associated with increased mortality, retrospective analyses revealed a decreased incidence of pneumonia and reduced mortality in COPD patients with hyperlipidemia <ref type="bibr" target="#b4">[4,</ref><ref type="bibr" target="#b5">5]</ref>. Thus the role of hyperlipidemia remains unclear and its relationship to other comorbidities, risk factors and pulmonary function has to be studied in more detail.</p><p>In subjects with metabolic syndrome and hyperlipidemia but no obvious lung disease a restrictive spirometric lung function pattern was observed <ref type="bibr" target="#b6">[6]</ref><ref type="bibr" target="#b7">[7]</ref><ref type="bibr" target="#b8">[8]</ref>, but this has not been verified e.g. by bodyplethysmography. The relation of hyperlipidemia to lung function in COPD is unclear but of interest owing to physiological findings. Lipoproteins can influence blood rheology, including plasma viscosity, aggregation and deformation of erythrocytes <ref type="bibr" target="#b9">[9,</ref><ref type="bibr" target="#b10">10]</ref>, and in vitro they led to accumulation of erythrocytes in the pulmonary capillary bed <ref type="bibr" target="#b11">[11]</ref>. Thus it has been hypothesized that a higher capillary red cell volume would lead to an increase in the diffusing capacity for carbon monoxide (TLCO). At least in lung-healthy subjects, however, there was no difference in TLCO between subjects with and without hyperlipidemia <ref type="bibr" target="#b11">[11]</ref><ref type="bibr" target="#b12">[12]</ref><ref type="bibr" target="#b13">[13]</ref>. Whether this also applies to patients with COPD is not known.</p><p>Based on these considerations the aim of our study was to analyze the relationship of hyperlipidemia to lung function, risk factors and comorbidities linked to hyperlipidemia in patients with COPD. For this purpose we used data from the German COSYCONET ("COPD and SYstemic consequences-COmorbidities NETwork") COPD cohort <ref type="bibr" target="#b14">[14]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Material and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p>The analysis was based on the baseline data set (visit 1) of COSYCONET which is a multicenter study focusing on the role of comorbidities in COPD <ref type="bibr" target="#b14">[14]</ref>. Only patients of COPD severity GOLD 1-4 <ref type="bibr" target="#b15">[15]</ref> with complete data on forced expiratory volume in 1 second (FEV 1 ), intrathoracic gas volume (ITGV) and transfer coefficient for carbon monoxide (KCO), as well as on age, gender, packyears of smoking, body-mass index (BMI) and the comorbidities hyperlipidemia, diabetes, and cardiovascular complex (see below) were included. This resulted in a study population of n = 1746 out of 2741 patients recruited into COSYCONET <ref type="bibr" target="#b14">[14]</ref>. The study had been approved by the ethical committees of all study centers and all patients gave their written informed consent.  <ref type="bibr" target="#b14">[14]</ref>. The approval by the central ethics committee (University of Marburg) and the ethics committees of all other studies centers (including University of Munich) comprises the statement that the study can be conducted. This includes not only the collection of data but also the permission that the analyses of the data outlined in the study protocol, as well as study questions developed on the basis of accumulated experience and the collected data, can be performed. An additional approval is only required if additional data are collected which were not part of the initial approval or if patient-sensitive analyses are to be performed, such as genetic analyses of collected samples without previous approval by the patient. In their written informed consent the patients also agreed to the scientific evaluation of the collected data. The specific aim of the present study, which comprised the analysis of three comorbidities and selected lung function parameters, is therefore implicitly included in the approval by the ethics committees. Naturally, in such a large cohort study including multiple parameters not all specific study questions can be explicitly formulated from the beginning. The question of the present study was contained in the bullet point "zu untersuchen, ob die Kombination funktioneller Indizes, systemischer Marker und klinischer Diagnosen es erlaubt, bislang unbekannte Pha ¨notypen der COPD zu definieren, die mo ¨glicherweise einer unterschiedlichen Verlaufskontrolle und Therapie bedu ¨rfen"(translated: to study whether the combination of functional indices, systemic markers and clinical diagnoses allows the definition of novel phenotypes of COPD which possibly require a different monitoring over time and therapy).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval and consent to participate</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>Protocol and methods have been described previously <ref type="bibr" target="#b14">[14]</ref>. To facilitate the comparison with previous cohorts we described the characteristics of our study population by a panel of parameters as well as the conventional categorizations (1-4 and ABCD) according to GOLD <ref type="bibr" target="#b15">[15]</ref>. Moreover we used the conventional percentages of mean predicted values based on the fact that the data on the deviations allowing for a lower limit of predicted was heterogeneous among the predictions equations for the different parameters used. For the present analysis comorbidities were assumed if either patients reported a doctor-based diagnosis, irrespective of medication, or in the absence of a report, if disease-specific medication was identified; the details of the procedure and the medication are given in a previous publication <ref type="bibr" target="#b16">[16]</ref>. These definitions were named "extended definitions". Since in cardiovascular diseases medication often is not specific for a single diagnosis but for two or three, we combined the three comorbidities "arterial hypertension", "cardiac failure" and "ischemic heart disease" into "cardiovascular complex" <ref type="bibr" target="#b16">[16]</ref>. The analysis was restricted to three comorbidities known to be closely linked to each other based on clinical observations. Moreover in these comorbidities disease-specific medication could be used to higher degree than in a variety of other comorbidities; the complete list of comorbidities is given in our previous publication <ref type="bibr" target="#b14">[14]</ref>.</p><p>Lung function comprised spirometry, body plethysmography and carbon monoxide (CO) diffusing capacity <ref type="bibr" target="#b14">[14]</ref>. In addition to FEV 1 , ITGV and KCO, for the description of the population the forced vital capacity (FVC), the ratio FEV 1 /FVC and transfer factor for CO (TLCO) were chosen, each as percent of predicted. For the path analysis FEV 1 , ITGV and KCO were taken as representatives of the domains obstruction, hyperinflation and gas exchange limitation. Predicted values of FEV 1 , FEV 1 /FVC, FVC were taken from GLI <ref type="bibr" target="#b17">[17]</ref>, of ITGV from EGKS <ref type="bibr" target="#b18">[18]</ref>, and of TLCO and KCO from van der Lee et al. <ref type="bibr" target="#b19">[19]</ref>. As major risk factors we included BMI, age, gender and packyears.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>Data are presented as mean values and standard deviations (SD). Comparisons between the two groups with and without hyperlipidemia were performed with the unpaired t-test irrespective of potential small deviations from normality (Kolmogorov-Smirnov-test) which commonly have no major impact on the test result. However, to be on the safe side and to check whether these deviations affected the result we additionally employed the Mann-Whitney-Utest and explicitly give the results for both types of tests. Categorical variables were compared between groups using cross-tabulation and the chi-square-test statistics.</p><p>Next the association between variables was evaluated by standard multivariate linear and binary logistic regression analyses comprising one dependent and multiple independent variables. These types of analyses are however limited to describe complex relationships in networks that can be represented by only two types of variables: dependent and independent. A potential relationship between dependent variables as well as the possibility that the same variable is both dependent and independent can be modeled by path analysis <ref type="bibr" target="#b20">[20]</ref>. All analyses were performed using SPSS Statistics 23 (IBM Corp., Armonk, NY, USA) and AMOS (IBM Corp., Armonk, NY, USA). Statistical significance was assumed for p&lt;0.05.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients' characteristics</head><p>Table <ref type="table" target="#tab_0">1</ref> shows the patients' characteristics (n = 1746) stratified for hyperlipidemia. In all parameters except for FVC%pred, FEV 1 /FVC and TLC%pred there were significant differences between the two groups, in both parametric and non-parametric testing. For comparison the values for the total COSYCONET study population (GOLD 1-4, n = 2238) are given in S1 Table ; patients with and without hyperlipidemia again significantly differed in all parameters except FEV 1 /FVC and TLC%pred. For selected lung function parameters the differences between hyperlipidemia groups remained significant after adjustment for risk factors and are illustrated in Fig <ref type="figure" target="#fig_1">1</ref>.</p><p>Fig <ref type="figure" target="#fig_2">2</ref> shows the prevalence of hyperlipidemia in patients with and without diabetes or cardiovascular complex. Both were significantly (p&lt;0.001 each) associated with hyperlipidemia. Overall these results showed that (a) our observations were in accordance with other cohorts and that (b) it would be reasonable to implement the relationships between comorbidities, and not only their relation to risk factors or lung function, into a statistical model.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results of path analysis models</head><p>We first performed standard multivariate linear and logistic regression analyses (see Tables A-C in S1 Text). Based on their results we constructed a sequence of path analysis models which allowed the description of more complex relationships, particularly between dependent variables. To build a final model in a systematic way, two preliminary models were evaluated (see S1 and S2 Figs). In this model the variables were arranged into three "layers": on top the risk factors (BMI, age, gender, packyears), as intermediates the comorbidities (diabetes, hyperlipidemia, cardiovascular complex), and at the bottom lung function (ITGV%pred, FEV 1 % pred, KCO%pred).</p><p>Final model comprising risk factors, comorbidities and lung function. The final model (Fig <ref type="figure" target="#fig_3">3</ref>) was constructed as a composite of the two preliminary models (S1 and S2 Figs). Based on the regression results (Table C in S1 Text) we additionally introduced a number of relationships between comorbidities and lung function but kept only those which turned out to be statistically significant, i.e. that between hyperlipidemia and ITGV and that between cardiovascular complex and FEV 1 . Parameter values and significance levels of the final model are shown in Table <ref type="table" target="#tab_2">2</ref>. The model fitted the data with a chi-squared of 18.79 at 21 degrees of freedom (p = 0.60; see above) and was also well-fitting according to the bootstrap procedure using 2000 samples and the Bollen-Stine method (chi-squared 21.54, p = 0.61).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>In the present analysis we investigated the relationship between risk factors, comorbidities and lung function in a large cohort of patients with COPD. The comorbidities comprised a combination of cardiovascular diseases and diabetes, as well as hyperlipidemia <ref type="bibr" target="#b2">[2,</ref><ref type="bibr" target="#b3">3]</ref>. Its prevalence was 42.9% according to self-reported doctors' diagnoses and disease-specific medication.</p><p>Based on linear and logistic regression results an integrative path analysis model was built that illustrated the place of hyperlipidemia in the network of risk factors, other comorbidities and lung function. Hyperlipidemia was dependent on age, BMI, diabetes and cardiovascular diseases. Even after adjustment for confounders it was associated with lower ITGV and higher FEV 1 , beyond the direct and indirect links from BMI and age. This apparently protective effect might be related to the phenotype of COPD as well as beneficial effects of medication targeted at hyperlipidemia. In our analyses we required complete data sets and therefore had to exclude a number of patients. However comparison of the descriptive Table <ref type="table" target="#tab_0">1</ref> and S1 To understand the relationship between the different entities we first performed multivariate regression analyses comprising the risk factors age, packyears, BMI and gender, the three comorbidities and a variety of lung function parameters. For path analysis we focused on single representatives of obstruction (FEV 1 %pred), hyperinflation (ITGV%pred) and gas exchange (KCO%pred). Among the comorbidities a combined entity "cardiovascular complex" was defined comprising arterial hypertension, cardiac failure and ischemic heart disease. The comorbidities depended on age, BMI and partially on gender (Table A in S1 Text), while lung function depended on BMI, age and gender, diffusing capacity additionally on packyears (Table B in S1 Text). Diabetes was related to lung volume and diffusing capacity, cardiovascular complex to obstruction and lung volume, and hyperlipidemia to all three lung function parameters (Table C in S1 Text).</p><p>Thus hyperlipidemia was linked to risk factors as well as lung function. It was associated with relatively better FEV 1 , while diabetes and cardiovascular complex were linked to relatively lower FEV 1 . The observation regarding hyperlipidemia and FEV 1 appeared to be in contrast to findings in obese lung-healthy subjects <ref type="bibr" target="#b21">[21]</ref> but in COPD the situation might be more complicated due to the presence of risk factors influencing both lung function and comorbidities. To analyse the complex network of direct and indirect effects we used the statistical procedure of path analysis.</p><p>Path analysis is a well-founded statistical procedure widely used in empirical social sciences and econometrics <ref type="bibr" target="#b20">[20]</ref>; it has also been used in medical studies to evaluate complex associations <ref type="bibr" target="#b22">[22,</ref><ref type="bibr" target="#b23">23]</ref>. Essentially it is an extension of multivariate regression allowing for hierarchical relationships as well as bypassing these hierarchies and thus the quantification of both direct and indirect effects all of which can be visualized graphically; indirect effects are those mediated through other variables (see S1 Text). The possibility to introduce relationships between These models showed that (a) the assumed additional relationships were statistically valid and (b) that no further significant relationships could be demonstrated. Irrespective of this it has to be kept in mind that path analysis is a hypothesis-driven procedure and that in general there may be statistically equivalent models. The choice between them has to be based on physiological and clinical knowledge. On the other hand the procedure is capable of excluding models that do not adequately describe the data <ref type="bibr" target="#b20">[20]</ref>.</p><p>The final model (Fig <ref type="figure" target="#fig_3">3</ref>) was constructed as overlay of the preliminary models. Additionally we introduced relationships between comorbidities and lung function taking into account the results of the respective regression analysis (Table C in S1 Text). Only the relationships between hyperlipidemia, FEV 1 %pred and ITGV%pred remained as significant and were kept in the model. It seems remarkable that these direct links from hyperlipidemia were still relevant when multiple confounders were taken into account but this was in accordance with comparisons adjusting for risk factors (Fig <ref type="figure" target="#fig_1">1</ref>). The link from hyperlipidemia to ITGV acted in parallel to the direct effect of BMI and had the same sign, i.e. hyperlipidemia was associated with less hyperinflation. This reduction of ITGV might reflect an additional mechanical influence in obese subjects that is not adequately described by BMI, such as a different distribution of body mass. To check this possibility we repeated the analysis with waist circumference as predictor instead of BMI. The overall model fit was still acceptable, and the links between hyperlipidemia and ITGV%pred as well as FEV 1 %pred remained significant. Therefore we considered BMI as adequate in the model.</p><p>Among the comorbidities of COPD known to be linked to hyperlipidemia, diabetes and cardiovascular diseases are the most prevalent ones <ref type="bibr" target="#b3">[3]</ref>. We therefore restricted the analysis to these two conditions. One of the advantages was that these comorbidities could also be evaluated via analysis of disease-specific medication in addition to patients' report <ref type="bibr" target="#b16">[16]</ref>. This however required that the three diseases arterial hypertension, cardiac failure and ischemic heart disease were combined into to a single entity termed "cardiovascular complex", since many medications are specific for a combination of these diseases but not for a single one.  shows the significance level based on the asymptotically distribution-free estimation procedure of AMOS. All coefficients were also significant when using the standard maximum likelihood estimation procedure despite the deviations from normal distribution for nearly all variables. The standardized estimates are given since they allow for the evaluation of direct and indirect effects: direct effects from one variable onto the other are given by the respective standardized regression coefficient, whereas indirect effects mediated through a third variable are given by the multiplication of the two standardized regression coefficients between the respective variables. The lower panel shows the covariances (bidirectional arrows) between the risk factors that were part of the model, as well as the respective standard errors, critical ratios and significance levels. The standardized covariances represent the respective correlation coefficients.</p><p><ref type="url" target="https://doi.org/10.1371/journal.pone.0177501.t002">https://doi.org/10.1371/journal.pone.0177501.t002</ref> </p><p>Comparing to reported diagnoses, the prevalence for diabetes increased through the consideration of specific medication from 12.6 to 12.9%, for the cardiovascular complex from 60.0 to 64.7%, and for hyperlipidemia from 37.9 to 42.9%. Probably the estimates including the information from medication are more reliable than those based on reports only. When using the latter, the overall fit of the model was reduced but still significant; importantly, the links between hyperlipidemia, ITGV and FEV 1 remained significant. This indicates that the extended definitions of comorbidities (a) improved the results and (b) did not introduce artefacts compared to the reported diagnoses.</p><p>As risk factors we considered age and gender, as well as packyears and BMI, which were either independent of the individual behaviour, or linked to lifestyle. All of them are known to be correlated with comorbidities and lung function, and indeed their association with cardiovascular diseases was consistent with previous findings <ref type="bibr" target="#b24">[24]</ref>. The same was true for the associations between BMI and hyperlipidemia <ref type="bibr" target="#b25">[25]</ref> or diabetes <ref type="bibr" target="#b26">[26]</ref>, or between diabetes and cardiovascular diseases <ref type="bibr" target="#b27">[27]</ref>, or between diabetes, cardiovascular diseases and hyperlipidemia <ref type="bibr" target="#b3">[3]</ref>. This suggests that the COSYCONET data set did not deviate from other data sets in a significant way, irrespective of the diagnosis of COPD. In particular this refers to the link between hyperlipidemia and lung volume which turned to be robust in various statistical analyses. The comorbidities were part of the final model in order to include as much as possible of the known confounders and thereby to identify both direct and indirect associations of hyperlipidemia via their standardized effects (see legend to Table <ref type="table" target="#tab_2">2</ref>). For example, hyperlipidemia was directly linked to age (Table <ref type="table" target="#tab_2">2</ref>; standardized effect 0.045; see also <ref type="bibr">Fig 2)</ref> but also indirectly linked to age via diabetes as well as cardiovascular complex which corresponded to an overall indirect effect of 0.039. Thus direct and indirect effects were of similar magnitude. This type of quantification is possible only with path analysis through multiplication of the respective standardized coefficients.</p><p>The findings regarding lung volume fit into the hypothesis that COPD patients with higher BMI and/or hyperlipidemia more often show a COPD phenotype of obstructive bronchitis rather than emphysema. We did not have such phenotype information, e.g. based on CT scans, and the pattern of lung function alterations did not uniquely allow the differentiation. The observed inverse association between ITGV and FEV 1 (Table <ref type="table" target="#tab_2">2</ref>) is known but not specific for emphysema <ref type="bibr" target="#b28">[28]</ref>, and the relationship between BMI and relatively higher FEV 1 is consistent with less emphysema in patients of higher weight <ref type="bibr" target="#b29">[29]</ref>. The direct link from packyears to lower KCO possibly reflected the degree of emphysema, thereby abolishing a potential effect of dyslipidemia (Fig <ref type="figure" target="#fig_1">1</ref>), and the association of higher ITGV with lower KCO (Table <ref type="table" target="#tab_2">2</ref>) their known volume-based relationship. As TLCO is directly proportional to lung volume we preferred the use of KCO, although KCO also does not fully normalize for volume. Moreover the model fit with KCO was superior to that with TLCO.</p><p>The positive association between hyperlipidemia and FEV 1 (Table <ref type="table" target="#tab_2">2</ref>) might be surprising at the first view but is not necessarily in conflict with findings that lung-healthy subjects with hyperlipidemia/metabolic syndrome showed a reduced FEV 1 , since we studied patients with COPD, i.e. inflammatory lung disease. Remarkably, patients with COPD and hyperlipidemia appear to have a better outcome in pneumonia-related exacerbations and mortality <ref type="bibr" target="#b4">[4,</ref><ref type="bibr" target="#b5">5]</ref>. It may also be noteworthy that several studies described an anti-inflammatory action of simvastatin <ref type="bibr" target="#b30">[30]</ref>, an improved FEV 1 in patients undergoing this therapy <ref type="bibr" target="#b31">[31]</ref> a protective effect against the development of emphysema <ref type="bibr" target="#b32">[32]</ref>, in accordance with the, on average, better FEV 1 and KCO in our patients (Table <ref type="table" target="#tab_0">1</ref>). Whether hyperlipidemia-related inflammation favours a specific phenotype of COPD is not known; for diabetes CT data indicate a predominant nonemphysematous type of COPD <ref type="bibr" target="#b33">[33]</ref>. Although the differences of lung function parameters between both groups were small, they might become relevant in case of exacerbations.</p><p>The diagnosis of hyperlipidemia used in our analyses was based on patients' reports and medication, while the effectiveness of their lipid-lowering therapy was illustrated by the comparison of patients with and without the diagnosis of hyperlipidemia (Table <ref type="table" target="#tab_0">1</ref> and<ref type="table" target="#tab_0">S1 Table)</ref>. This was the reason why we could not use lipids for the definition of hyperlipidemia and did not include them into the path analysis. Overall 23.8% of patients received hyperlipidemia-specific medication <ref type="bibr" target="#b20">[20]</ref>, the others either non-specific medication and/or dietetics recommendations. When ITGV%pred was evaluated with BMI, age, gender and packyears as confounders, it turned out to be still significantly reduced for both patients with specific and non-specific medication. These observations show that the major difference in patients with the diagnosis of hyperlipidemia compared to those without was the presence of medication and not an increase in lipid levels. It is therefore tempting to attribute our findings to effects of medication.</p><p>One of the limitations of our study was that we could characterize the population by conventional lipid parameters but hardly include these in the analyses since they apparently were affected by therapy. A similar situation occurred for cardiovascular diseases. We therefore preferred not to use biomarkers in this analysis. The identification of comorbidities was based on patients' reports only but we tried to alleviate this limitation as much as possible by using the extended, medication-based definitions. Moreover we did not have detailed information on the phenotype of COPD, e.g. from CT scans. The strength of the study was the large data set, the possibility to evaluate three comorbidities by analysis of medication, and the use of path analysis beyond conventional multivariate regression. The statistical evaluation of the model depended on assumptions on data distribution which were not met with our data, but we used asymptotically distribution-free estimation in a sufficiently large data set <ref type="bibr" target="#b24">[24]</ref> and the fit was confirmed by other estimation procedures. Furthermore we incorporated into the final model as much as possible of the already known associations thereby aiming to describe the role of hyperlipidemia in COPD in the whole context of other alterations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>Using the large baseline data set of the German COPD cohort COSYCONET we evaluated the relationship between risk factors, hyperlipidemia, diabetes, a combination of cardiovascular diseases and lung function. Hyperlipidemia was associated with lower ITGV and higher FEV 1 even if its direct and indirect links to diabetes and cardiovascular disease, or age, gender and BMI were taken into account, and there was no hint towards an impairment of lung function associated with hyperlipidemia, similar to that previously found for diabetes. The result was statistically robust within a path analysis model and multivariate regression analyses suggesting that COPD patients with hyperlipidemia showed less lung hyperinflation and airway obstruction than those without hyperlipidemia. Whether this reflected differences in COPD phenotype or was related to other factors including medication remains to be clarified.  . Baseline characteristics of the subgroups with and without hyperlipidemia (n = 2238, total cohort GOLD 1-4). The table shows mean values and standard deviations or absolute numbers. Lung function parameters are given in terms of %predicted, except for alveolar volume, VA, which is given in liters. Column 4 shows the results of comparisons between the hyperlipidemia group (extended definition) and the complementary group of non-hyperlipidemia patients. The comparisons between groups were performed by unpaired t-tests, either for equal or unequal variances depending on the data, or by chi-square-tests in the case of categorical variables. The results of t-tests were checked by the Mann-Whitney-Utest to accommodate for deviations from normality; the results of both approaches were qualitatively equivalent. Significant (p&lt;0.05) differences are marked with ( Ã ). </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>All assessments were approved by the central (Marburg (Ethikkommission FB Medizin Marburg) and local (Bad Reichenhall (Ethikkommission bayerische Landesa ¨rztekammer); Berlin (Ethikkommission A ¨rztekammer Berlin); Bochum (Ethikkommission Medizinische Fakulta ¨t der RUB); Borstel (Ethikkommission Universita ¨t Lu ¨beck); Coswig (Ethikkommission TU Dresden); Donaustauf (Ethikkommission Universita ¨tsklinikum Regensburg); Essen (Ethikkommission Medizinische Fakulta ¨t Duisburg-Essen); Gießen (Ethikkommission Fachbereich Medizin); Greifswald (Ethikkommission Universita ¨tsmedizin Greifswald); Großhansdorf (Ethikkommission A ¨rztekammer Schleswig-Holstein); Hamburg (Ethikkommission A ¨rztekammer Hamburg); MHH Hannover / Coppenbru ¨gge (MHH Ethikkommission); Heidelberg Thorax/Uniklinik (Ethikkommission Universita ¨t Heidelberg); Homburg (Ethikkommission Saarbru ¨cken); Immenhausen (Ethikkommission Landesa ¨rztekammer Hessen); Kiel (Ethikkommission Christian-Albrechts-Universita ¨t zu Kiel); Leipzig (Ethikkommission Universita ¨t Leipzig); Lo ¨wenstein (Ethikkommission Landesa ¨rztekammer Baden-Wu ¨rttemberg); Mainz (Ethikkommission Landesa ¨rztekammer Rheinland-Pfalz); Mu ¨nchen LMU/Gauting (Ethikkommission Klinikum Universita ¨t Mu ¨nchen); Nu ¨rnberg (Ethikkommission Friedrich-Alexander-Universita ¨t Erlangen Nu ¨rnberg); Rostock (Ethikkommission Universita ¨t Rostock); Berchtesgadener Land (Ethikkommission Land Salzburg); Schmallenberg (Ethikkommission A ¨rztekammer Westfalen-Lippe); Solingen (Ethikkommission Universita ¨t Witten-Herdecke); Ulm (Ethikkommission Universita ¨t Ulm); Wu ¨rzburg(Ethikkommission Universita ¨t Wu ¨rzburg)) ethical committees and written informed consent was obtained from all patients. The study was conducted from September 2011 to December 2013 within the COSYCONET framework (ClinicalTrials.gov, Identifier: NCT01245933)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig 1 .</head><label>1</label><figDesc>Fig 1. Adjusted effects of hyperlipidemia on lung function. The figure shows the differences between patients with and without hyperlipidemia for three selected lung function parameters representing airway obstruction, lung volume and alveolar gas exchange. These differences are based on multivariate regression analyses adjusting for age, gender, BMI and packyears, as major confounders some of which were different between groups. The circles represent mean values and the vertical bars 95% confidence intervals, showing that even after adjustment there were significant (p&lt;0.05) differences in FEV 1 and ITGV. https://doi.org/10.1371/journal.pone.0177501.g001</figDesc><graphic coords="6,95.98,78.01,479.91,283.46" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig 2 .</head><label>2</label><figDesc>Fig 2. Prevalence of hyperlipidemia versus diabetes and cardiovascular complex. Diabetes and cardiovascular complex were associated with hyperlipidemia. Significant differences (p&lt;0.001) were marked with (*). https://doi.org/10.1371/journal.pone.0177501.g002</figDesc><graphic coords="7,95.98,78.01,479.91,290.21" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig 3 .</head><label>3</label><figDesc>Fig 3. Results of path analysis. Final path analysis model comprising three layers: risk factors, comorbidities and lung function parameters. The structure only contains relationships which turned out to be statistically significant (p&lt;0.05 each). Error terms of dependent variables have been omitted for the sake of clarity. Correlations between the independent variables are indicated by arched arrows. https://doi.org/10.1371/journal.pone.0177501.g003</figDesc><graphic coords="8,95.98,78.01,479.91,287.77" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc>The upper panel refers to the directed arrows (linear regression terms) depicted in Fig 2. The left part of this panel lists the arrows shown in this figure, the right part shows the results of the corresponding statistical tests. The first column of the right part shows the non-standardized estimate of the respective regression coefficient, the second column the standard error of this coefficient (S.E.), the third column the ratio of these two (critical ratio. C.R.) which is used for significance testing. The forth column shows the standardized estimates of the regression coeffients shown in the first column. The last column</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>S2 Fig. Preliminary path analysis model 2 .</head><label>2</label><figDesc>Preliminary path analysis model comprising two layers, on the top risk factors and as bottom layer lung function parameters. All of the relationships shown were statistically significant (p&lt;0.05 each). Error terms of dependent variables have been omitted for the sake of clarity. There were no significant correlations between the independent variables. (TIF)S1 Table</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 . Baseline characteristics of the subgroups with and without hyperlipidemia.</head><label>1</label><figDesc></figDesc><table><row><cell>Parameter</cell><cell>All patients</cell><cell>Hyperlipidemia</cell><cell>Non-Hyperlipidemia</cell><cell>p-values</cell></row><row><cell></cell><cell></cell><cell>(extended def.)</cell><cell></cell><cell></cell></row><row><cell>N (%)</cell><cell>1746</cell><cell>749 (42.9%)</cell><cell>997 (57.1%)</cell><cell>-</cell></row><row><cell>Gender (m/f)</cell><cell>1092/654</cell><cell>498/251</cell><cell>594/403</cell><cell>p = 0.003*</cell></row><row><cell>Age (y)</cell><cell>64.6 (±8.4)</cell><cell>65.8 (±7.8)</cell><cell>63.8 (±8.8)</cell><cell>p&lt;0.001*</cell></row><row><cell>BMI (kg/m 2 )</cell><cell>26.8 (±5.3)</cell><cell>27.6 (±5.2)</cell><cell>26.2 (±5.2)</cell><cell>p&lt;0.001*</cell></row><row><cell>Waist circ. (cm)</cell><cell>99.6 (±15.6)</cell><cell>102.1 (±15.3)</cell><cell>97.7 (±15.5)</cell><cell>p&lt;0.001*</cell></row><row><cell>Packyears</cell><cell>49.2 (±35.8)</cell><cell>52.4 (±37.8)</cell><cell>46.7 (±34.0)</cell><cell>p = 0.001*</cell></row><row><cell>Hb (mg/dl)</cell><cell>14.71 (±1.34)</cell><cell>14.59 (±1.42)</cell><cell>14.79 (±1.29)</cell><cell>p = 0.003*</cell></row><row><cell>Creatinine (mg/dl)</cell><cell>0.90 (±0.24)</cell><cell>0.93 (±0.26)</cell><cell>0.87 (±0.22)</cell><cell>p&lt;0.001*</cell></row><row><cell>Triglycerides (md/dl)</cell><cell>141.5 (±106.6)</cell><cell>156.9 (±111.1)</cell><cell>129.9 (±101.7)</cell><cell>p&lt;0.001*</cell></row><row><cell>Total cholesterol (mg/dl)</cell><cell>214.2 (±43.4)</cell><cell>209.6 (±48.2)</cell><cell>217.8 (±39.1)</cell><cell>p&lt;0.001*</cell></row><row><cell>LDL (mg/dl)</cell><cell>126.8 (±38.0)</cell><cell>123.1 (±41.5)</cell><cell>129.5 (±34.9)</cell><cell>p 0.001*</cell></row><row><cell>HDL (mg/dl)</cell><cell>64.1 (±20.9)</cell><cell>61.9 (±20.8)</cell><cell>65.8 (±20.9)</cell><cell>p&lt;0.001*</cell></row><row><cell>FEV 1 %pred</cell><cell>56.9 (±19.1)</cell><cell>58.6 (±18.8)</cell><cell>55.6 (±19.3)</cell><cell>p = 0.001*</cell></row><row><cell>FEV 1 /FVC</cell><cell>54.7 (±13.8)</cell><cell>55.0 (±13.6)</cell><cell>54.6 (±19.3)</cell><cell>p = 0.451</cell></row><row><cell>FVC%pred</cell><cell>78.3 (±19.1)</cell><cell>77.6 (±19.3)</cell><cell>78.9 (±19.0)</cell><cell>p = 0.166</cell></row><row><cell>TLC%pred</cell><cell>110.9 (±29.8)</cell><cell>109.8 (±29.0)</cell><cell>111.7 (±30.3)</cell><cell>p = 0.188</cell></row><row><cell>RV%pred</cell><cell>153.9 (±45.3)</cell><cell>148.0 (±42.5)</cell><cell>158.4 (±46.9)</cell><cell>p&lt;0.001*</cell></row><row><cell>ITGV%pred</cell><cell>149.4 (±35.0)</cell><cell>144.1 (±33.9)</cell><cell>153.3 (±35.2)</cell><cell>p&lt;0.001*</cell></row><row><cell>VA (liter)</cell><cell>4.7 (±1.6)</cell><cell>4.8 (±1.6)</cell><cell>4.7 (±1.7)</cell><cell>p = 0.316</cell></row><row><cell>TLCO%pred</cell><cell>50.6 (±19.7)</cell><cell>52.1 (±19.1)</cell><cell>49.5 (± 20.1)</cell><cell>p = 0.006*</cell></row><row><cell>KCO%pred</cell><cell>64.0 (±22.4)</cell><cell>66.5 (±22.1)</cell><cell>62.1 (±22.6)</cell><cell>p&lt;0.001*</cell></row><row><cell>GOLD 1/2/3/4</cell><cell>232/934/24/584</cell><cell>106/367/242/34</cell><cell>126/438/363/70</cell><cell>p = 0.022*</cell></row><row><cell>GOLD A/B/C/D</cell><cell>199/934/24/582</cell><cell>82/396/6/264</cell><cell>117/538/18/318</cell><cell>p = 0.123</cell></row></table><note><p>The table shows mean values and standard deviations or absolute numbers. Lung function parameters are given in terms of %predicted, except for alveolar volume, VA, which is given in liters. Column 4 shows the results of comparisons between the hyperlipidemia group (extended definition) and the complementary group of non-hyperlipidemia patients. The comparisons between groups were performed by unpaired t-tests, either for equal or unequal variances depending on the data, or by chi-square-tests in the case of categorical variables. The results of t-tests were checked by the Mann-Whitney-Utest to accommodate for deviations from normality; the results of both approaches were qualitatively equivalent. Significant (p&lt;0.05) differences are marked with (*). https://doi.org/10.1371/journal.pone.0177501.t001</p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 . Results of the final path analysis model.</head><label>2</label><figDesc></figDesc><table><row><cell>Regression</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p>PLOS ONE | https://doi.org/10.1371/journal.pone.0177501May 15, 2017  </p></note>
		</body>
		<back>

			
			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p>COSYCONET consortium</p></div>
			</div>


			<div type="funding">
<div><p>This work was supported by <rs type="funder">BMBF Competence Network Asthma and COPD (ASCONET)</rs> and performed in collaboration with the <rs type="institution">German Center for Lung Research (DZL)</rs>. The project is funded by the <rs type="funder">German Federal Ministry of Education and Research (BMBF)</rs> with grant number <rs type="grantNumber">01 GI 0881</rs>; and is funded by unrestricted grants from <rs type="affiliation">AstraZeneca GmbH, Bayer Schering Bals</rs> reports grants from <rs type="funder">Grifols</rs>, personal fees from <rs type="funder">GSK</rs>, <rs type="institution">AstraZeneca</rs>, <rs type="funder">Boehringer Ingelheim</rs>, outside the submitted work; <rs type="person">Dr. Ficker</rs> reports grants from Cosyconet study supported by <rs type="funder">Bundesministerium fuer Bildung und Forschung BMBF</rs>, during the conduct of the study; personal fees from Boehringer, grants, personal fees and non-financial support from <rs type="funder">CSL-Behring</rs>, personal fees from <rs type="funder">GSK</rs>, personal fees from <rs type="funder">AstraZeneca</rs>, personal fees from <rs type="funder">Roche</rs>, personal fees and non-financial support from <rs type="funder">Novartis</rs>, from null, outside the submitted work; <rs type="person">Dr. Fa</rs> ¨hndrich reports grants from <rs type="funder">CSL Behring</rs>, grants from <rs type="funder">Grifols</rs>, grants from <rs type="funder">AstraZeneca</rs>, outside the submitted work; <rs type="person">Dr. Holle</rs> reports grants from <rs type="funder">German Federal Ministry of Education and Research</rs> (grant number <rs type="grantNumber">01GI0882</rs>), during the conduct of the study; <rs type="person">Dr. Karrasch</rs> reports grants from <rs type="funder">German Federal Ministry of Education and Research (BMBF)</rs> with grant number <rs type="grantNumber">01GI0882</rs>, during the conduct of the study; <rs type="person">Dr. Wacker</rs> reports grants from <rs type="funder">German Federal Ministry of Education and Research</rs> (grant number <rs type="grantNumber">01GI0882</rs>),</p><p>during the conduct of the study;<rs type="person">Dr. Vogelmeier</rs> reports personal fees from <rs type="institution">Almirall</rs>, personal fees from <rs type="funder">AstraZeneca</rs>, personal fees from <rs type="funder">Boehringer Ingelheim</rs>, personal fees from <rs type="funder">Chiesi</rs>, grants and personal fees from <rs type="funder">GlaxoSmithKline</rs>, grants and personal fees from <rs type="funder">Grifols</rs>, personal fees from Mundipharma, personal fees from <rs type="funder">Novartis</rs>, personal fees from <rs type="funder">Takeda</rs>, personal fees from <rs type="funder">Cipla</rs>, personal fees from <rs type="funder">Berlin Chemie/Menarini</rs>, outside the submitted work; <rs type="person">Dr. Jo</rs> ¨rres reports grants from <rs type="funder">German Federal Ministry of Education and Research</rs> (grant number <rs type="grantNumber">01GI0882</rs>), during the conduct of the study, as well as Grants from <rs type="funder">MundiPharma</rs>, <rs type="funder">GSK</rs> and <rs type="person">Lufthansa</rs> that are not related to the present work.</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_ZWDZRTM">
					<idno type="grant-number">01 GI 0881</idno>
				</org>
				<org type="funding" xml:id="_xvzkKHV">
					<idno type="grant-number">01GI0882</idno>
				</org>
				<org type="funding" xml:id="_FzSwT6u">
					<idno type="grant-number">01GI0882</idno>
				</org>
				<org type="funding" xml:id="_Jca7jD4">
					<idno type="grant-number">01GI0882</idno>
				</org>
				<org type="funding" xml:id="_etF6HK8">
					<idno type="grant-number">01GI0882</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>All relevant data are within the paper and its Supporting Information files.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting information</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m">Steering Committee): Prof. Dr. Claus Vogelmeier Email: claus.vogelmeier@med.uni-marburg.de Study site/ prinicpal investigator Philipps-Universita ¨t</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">New and emerging risk factors for coronary heart disease</title>
		<author>
			<persName><forename type="first">E</forename><surname>Akhabue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thiboutot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Vittorio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Christodoulidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Grady</surname></persName>
		</author>
		<idno type="DOI">10.1097/MAJ.0b013e31828aab45</idno>
		<idno type="PMID">23644407</idno>
		<ptr target="https://doi.org/10.1097/MAJ.0b013e31828aab45" />
	</analytic>
	<monogr>
		<title level="j">Am J Med Sci</title>
		<imprint>
			<biblScope unit="volume">347</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="151" to="158" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Comorbidities in chronic obstructive pulmonary disease</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Chatila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Thomashow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Minai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Criner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Make</surname></persName>
		</author>
		<idno type="DOI">10.1513/pats.200709-148ET</idno>
		<idno type="PMID">18453370</idno>
		<ptr target="https://doi.org/10.1513/pats.200709-148ET" />
	</analytic>
	<monogr>
		<title level="j">Proc Am Thorac Soc</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="549" to="555" />
			<date type="published" when="2008-05-06">2008. 2008/05/06</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Comorbidity in chronic obstructive pulmonary disease</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Negewo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Mcdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Gibson</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.resinv.2015.02.004</idno>
		<idno type="PMID">26521102</idno>
		<ptr target="https://doi.org/10.1016/j.resinv.2015.02.004" />
	</analytic>
	<monogr>
		<title level="j">Respir Investig</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="249" to="258" />
			<date type="published" when="2015">2015. 2015/11/02</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Hyperlipidemia in COPD is associated with decreased incidence of pneumonia and mortality: a nationwide health insurance data-based retrospective cohort study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">R</forename><surname>Kou</surname></persName>
		</author>
		<idno type="DOI">10.2147/COPD.S102708</idno>
		<idno type="PMID">27274227</idno>
		<ptr target="https://doi.org/10.2147/COPD.S102708" />
	</analytic>
	<monogr>
		<title level="j">Int J Chron Obstruct Pulmon Dis</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1053" to="1059" />
			<date type="published" when="2016-06-09">2016. 2016/06/09</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Divo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>De Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Casanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Marin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Pinto-Plata</surname></persName>
		</author>
		<idno type="DOI">10.1164/rccm.201201-0034OC</idno>
		<idno type="PMID">22561964</idno>
		<ptr target="https://doi.org/10.1164/rccm.201201-0034OC" />
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="155" to="161" />
			<date type="published" when="2012-05-09">2012. 2012/05/09</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Lung function and metabolic syndrome: Findings of National Health and Nutrition Examination Survey 2007-2010</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">I</forename><surname>Mercado</surname></persName>
		</author>
		<idno type="DOI">10.1111/1753-0407.12136</idno>
		<idno type="PMID">26677470</idno>
		<ptr target="https://doi.org/10.1111/1753-0407.12136" />
	</analytic>
	<monogr>
		<title level="j">J Diabetes</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="603" to="613" />
			<date type="published" when="2014">2014. 2015/12/ 18</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Relationship between lung function and metabolic syndrome</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Kao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0108989</idno>
		<idno type="PMID">25299452</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0108989" />
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">108989</biblScope>
			<date type="published" when="2014">2014. 2014/10/10</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Relationships of decreased lung function with metabolic syndrome and obstructive sleep apnea in Japanese males</title>
		<author>
			<persName><forename type="first">C</forename><surname>Yoshimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Oga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Takegami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sumi</surname></persName>
		</author>
		<idno type="PMID">22975537</idno>
	</analytic>
	<monogr>
		<title level="j">Intern Med</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="2291" to="2297" />
			<date type="published" when="2012-09-15">2012. 2012/09/15</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Reduced plasma high-density lipoprotein and increased platelet activity in arterial versus venous blood</title>
		<author>
			<persName><forename type="first">M</forename><surname>Aviram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Viener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Brook</surname></persName>
		</author>
		<idno type="PMID">3671249</idno>
	</analytic>
	<monogr>
		<title level="j">Postgrad Med J</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">736</biblScope>
			<biblScope unit="page" from="91" to="94" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Increased blood viscosity and fibrinolytic inhibitor in type II hyperlipoproteinaemia</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Lowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Mcardle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stromberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Lorimer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Forbes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Prentice</surname></persName>
		</author>
		<idno type="PMID">6121140</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">8270</biblScope>
			<biblScope unit="page" from="472" to="475" />
			<date type="published" when="1982">1982. 1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Effect of simvastatin on micropulmonary red cell mass in patients with hyperlipoproteinemia</title>
		<author>
			<persName><forename type="first">I</forename><surname>Pintaric</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Eterovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tocilj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Reiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lusic</surname></persName>
		</author>
		<idno type="PMID">11166784</idno>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="493" to="496" />
			<date type="published" when="2001">2001. 2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Effect of elevated triglycerides on the diffusing capacity of man</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Newball</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Friedewald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Lenfant</surname></persName>
		</author>
		<idno type="PMID">1147387</idno>
	</analytic>
	<monogr>
		<title level="j">Am Rev Respir Dis</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="83" to="88" />
			<date type="published" when="1975">1975</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Effect of hyperlipidaemia on pulmonary diffusing capacity for carbon monoxide</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Partridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Thompson</surname></persName>
		</author>
		<idno type="PMID">483198</idno>
	</analytic>
	<monogr>
		<title level="j">Thorax</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="265" to="268" />
			<date type="published" when="1979">1979</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline</title>
		<author>
			<persName><forename type="first">A</forename><surname>Karch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vogelmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Welte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bals</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">U</forename><surname>Kauczor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Biederer</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.rmed.2016.03.008</idno>
		<idno type="PMID">27109808</idno>
		<ptr target="https://doi.org/10.1016/j.rmed.2016.03.008" />
	</analytic>
	<monogr>
		<title level="j">Respir Med</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="27" to="37" />
			<date type="published" when="2016-04-26">2016. 2016/04/26</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Soriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lamprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Ramirez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martinez-Camblor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Alfageme</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2213-2600(15)00157-5</idno>
		<idno type="PMID">25995071</idno>
		<ptr target="https://doi.org/10.1016/S2213-2600(15)00157-5" />
	</analytic>
	<monogr>
		<title level="j">Lancet Respir Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="443" to="450" />
			<date type="published" when="2015-05-23">2015. 2015/05/23</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies-A Novel Stepwise Approach by Evaluation of Medication</title>
		<author>
			<persName><forename type="first">T</forename><surname>Lucke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Herrera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Holle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Biertz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nowak</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0163408</idno>
		<idno type="PMID">27792735</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0163408" />
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">163408</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Quanjer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stanojevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Cole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Baur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Culver</surname></persName>
		</author>
		<idno type="DOI">10.1183/09031936.00080312</idno>
		<idno type="PMID">22743675</idno>
		<ptr target="https://doi.org/10.1183/09031936.00080312" />
	</analytic>
	<monogr>
		<title level="j">Eur Respir J</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1324" to="1343" />
			<date type="published" when="2012-06-30">2012. 2012/06/30</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Lung volumes and forced ventilatory flows</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Quanjer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Tammeling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cotes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">F</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Peslin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yernault</surname></persName>
		</author>
		<idno type="PMID">8499054</idno>
	</analytic>
	<monogr>
		<title level="m">Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal</title>
		<imprint>
			<publisher>European Respiratory Society</publisher>
			<date type="published" when="1993">1993</date>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="5" to="40" />
		</imprint>
	</monogr>
	<note>Official Statement of the</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Diffusing capacity for nitric oxide: reference values and dependence on alveolar volume</title>
		<author>
			<persName><forename type="first">I</forename><surname>Van Der Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zanen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Stigter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Van Den Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Lammers</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.rmed.2006.12.001</idno>
		<idno type="PMID">17229562</idno>
		<ptr target="https://doi.org/10.1016/j.rmed.2006.12.001" />
	</analytic>
	<monogr>
		<title level="j">Respir Med</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1579" to="1584" />
			<date type="published" when="2007-01-19">2007. 2007/ 01/19</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m">Handbook of Structural Equation Modeling</title>
		<editor>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Hoyle</surname></persName>
		</editor>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Lung function impairment and metabolic syndrome: the critical role of abdominal obesity</title>
		<author>
			<persName><forename type="first">N</forename><surname>Leone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Courbon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jego</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Leynaert</surname></persName>
		</author>
		<idno type="DOI">10.1164/rccm.200807-1195OC</idno>
		<idno type="PMID">19136371</idno>
		<ptr target="https://doi.org/10.1164/rccm.200807-1195OC" />
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">179</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="509" to="516" />
			<date type="published" when="2009">2009. 2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tawakol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ishai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Takx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Figueroa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ali</forename><forename type="middle">A</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename></persName>
		</author>
		<idno>2017/01/16</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Pathways to perinatal depressive symptoms after mass conflict in Timor-Leste: a modelling analysis using cross-sectional data</title>
		<author>
			<persName><forename type="first">D</forename><surname>Silove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rees</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Tay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">M</forename><surname>Da Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Savio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Soares</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2215-0366(14)00054-6</idno>
		<idno type="PMID">26359752</idno>
		<ptr target="https://doi.org/10.1016/S2215-0366(14)00054-6" />
	</analytic>
	<monogr>
		<title level="j">Lancet Psychiatry</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="161" to="167" />
			<date type="published" when="2015-09-12">2015. 2015/09/12</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title level="m" type="main">Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation</title>
		<author>
			<persName><forename type="first">P</forename><surname>Jousilahti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vartiainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tuomilehto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Puska</surname></persName>
		</author>
		<idno type="PMID">10069784</idno>
		<imprint>
			<date type="published" when="1999">1999</date>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="1165" to="1172" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Relationship of body mass index and dyslipidemia in different age groups of male and female population of Peshawar</title>
		<author>
			<persName><forename type="first">A</forename><surname>Humayun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Alam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hussein</surname></persName>
		</author>
		<idno type="PMID">20524492</idno>
	</analytic>
	<monogr>
		<title level="j">J Ayub Med Coll Abbottabad</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="141" to="144" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Bays</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Grandy</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1742-1241.2007.01336.x</idno>
		<idno type="PMID">17493087</idno>
		<ptr target="https://doi.org/10.1111/j.1742-1241.2007.01336.x" />
	</analytic>
	<monogr>
		<title level="j">Int J Clin Pract</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="737" to="747" />
			<date type="published" when="2007-05-12">2007. 2007/05/12</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Grundy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Benjamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Burke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chait</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Eckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">V</forename><surname>Howard</surname></persName>
		</author>
		<idno type="PMID">10477542</idno>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1134" to="1146" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Santus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Radovanovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Henchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Marco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Centanni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D'</forename><surname>Angelo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.resp.2014.03.012</idno>
		<idno type="PMID">24726342</idno>
		<ptr target="https://doi.org/10.1016/j.resp.2014.03.012" />
	</analytic>
	<monogr>
		<title level="j">Respir Physiol Neurobiol</title>
		<imprint>
			<biblScope unit="volume">197</biblScope>
			<biblScope unit="page" from="36" to="45" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">The relation of body mass index to asthma, chronic bronchitis, and emphysema</title>
		<author>
			<persName><forename type="first">S</forename><surname>Guerra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Sherrill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bobadilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Barbee</surname></persName>
		</author>
		<idno type="PMID">12377850</idno>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1256" to="1263" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Albert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Danielson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rifai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Ridker</surname></persName>
		</author>
		<idno type="PMID">11434828</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">286</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="64" to="70" />
			<date type="published" when="2001">2001. 2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">An epidemiological study of the effects of statin use on airflow limitation in patients with chronic obstructive pulmonary disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bando</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miyazawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shinohara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Owada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Terakado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sugiyama</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1440-1843.2011.02116.x</idno>
		<idno type="PMID">22142478</idno>
		<ptr target="https://doi.org/10.1111/j.1440-1843.2011.02116.x" />
	</analytic>
	<monogr>
		<title level="j">Respirology</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="493" to="498" />
			<date type="published" when="2011">2012. 2011/12/07</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Simvastatin inhibits cigarette smokinginduced emphysema and pulmonary hypertension in rat lungs</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Choe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Shim</surname></persName>
		</author>
		<idno type="DOI">10.1164/rccm.200501-041OC</idno>
		<idno type="PMID">16002570</idno>
		<ptr target="https://doi.org/10.1164/rccm.200501-041OC" />
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="987" to="993" />
			<date type="published" when="2005">2005. 2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Hersh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Make</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Lynch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Barr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Bowler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Calverley</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2466-14-164</idno>
		<idno type="PMID">25341556</idno>
		<ptr target="https://doi.org/10.1186/1471-2466-14-164" />
	</analytic>
	<monogr>
		<title level="j">BMC Pulm Med</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">164</biblScope>
			<date type="published" when="2014">2014. 2014/10/25</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
